VATE INNOVATE Corp.

NYSE innovatecorp.com


$ 5.30 $ -0.45 (-8.04 %)    

Friday, 14-Nov-2025 15:50:51 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 5.15
$ 5.49
$ 5.30 x 3
$ 5.41 x 27
$ 5.50 - $ 5.51
$ 3.81 - $ 13.79
19,857
na
70.32M
$ 1.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-06-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-06-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-09-2023 06-30-2023 10-Q
11 05-10-2023 03-31-2023 10-Q
12 03-14-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 03-09-2022 12-31-2021 10-K
17 11-04-2021 09-30-2021 10-Q
18 08-06-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-10-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-12-2019 12-31-2018 10-K
29 11-06-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-10-2018 05-10-2018 10-Q
32 03-14-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-09-2017 06-30-2017 10-Q
35 05-10-2017 03-31-2017 10-Q
36 03-09-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-09-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 innovate-q3-eps-071-up-from-118-yoy-sales-347100m-up-from-242200m-yoy

Innovate (NYSE:VATE) reported quarterly losses of $(0.71) per share. This is a 39.83 percent increase over losses of $(1.18) pe...

 innovate-announces-medibeacons-transdermal-gfr-system-receives-nmpa-approval-in-china-plans-year-end-launch

•MediBeacon®Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patient...

 innovate-q2-eps-167-down-from-100-yoy-sales-24200m-down-from-31310m-yoy

Innovate (NYSE:VATE) reported quarterly losses of $(1.67) per share. This is a 267 percent decrease over earnings of $1.00 per ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION